SLC5A2 and metabolic dysfunction-associated steatotic liver disease: <h4>Background</h4>The purpose of our study was to assess the effect of sodium-glucose cotransporter protein 2 (SGLT-2) inhibitors on the progression of liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD), which is currently renamed metabolic dysfunction-associated steatohepatitis (MASLD).<h4>Methods</h4>From database establishment to February 2025, we systematically searched electronic databases, including PubMed, Web of Science, Embase, and the Cochrane Library, to identify relevant randomized controlled trials (RCTs).